T-CONTROL

Donor T Cells for Immune Control

Coordinatore	UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT    more  Organization address address: JOSEF-SCHNEIDER-STRASSE 2 city: WUERZBURG postcode: 97080 contact info Titolo: Ms. Nome: Anne Cognome: Von Thun Email: send email Telefono: +49 931 201 56436 Fax: +49 931 201 656430
Nazionalità Coordinatore	Germany [DE]
Totale costo	7˙410˙741 €
EC contributo	5˙682˙536 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-2
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-05-01   -   2016-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT  Organization address address: JOSEF-SCHNEIDER-STRASSE 2 city: WUERZBURG postcode: 97080 contact info Titolo: Ms. Nome: Anne Cognome: Von Thun Email: send email Telefono: +49 931 201 56436 Fax: +49 931 201 656430	DE (WUERZBURG)	coordinator	980˙892.00
2	STAGE CELL THERAPEUTICS GMBH  Organization address address: RUDOLF-WISSELL-STRASS 28 city: GOETTINGEN postcode: 37079 contact info Titolo: Dr. Nome: Lothar Cognome: Germeroth Email: send email Telefono: +49 55150672111 Fax: +49 55150672181	DE (GOETTINGEN)	participant	2˙531˙268.00
3	ANTHONY NOLAN  Organization address address: AGINCOURT ROAD 75-87 UNITS 2-3 HEATHGATE PLACE city: LONDON postcode: NW3 2NU contact info Titolo: Prof. Nome: Alejandro Cognome: Madrigal Email: send email Telefono: +44 2072848315 Fax: +44207 284 3338	UK (LONDON)	participant	931˙276.00
4	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Prof. Nome: Frederik Cognome: Falkenburg Email: send email Telefono: +31 715262271 Fax: +31 715266755	NL (LEIDEN)	participant	929˙100.00
5	GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O  Organization address address: Oskar-von-Miller-Ring 29 city: MUENCHEN postcode: 80333 contact info Titolo: Mrs. Nome: Birgit Cognome: Fuchs Email: send email Telefono: +49 8928810414 Fax: +49 8928810420	DE (MUENCHEN)	participant	310˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Patients with high-risk hematological tumors can be cured by allogeneic hematopoietic stem cell transplantation (HSCT). However, the main causes of failure of HSCT are infections, tumor relapse and over-shooting immune responses of the donor T cells to healthy cells and tissues of the patient or graft-versus host disease (GvHD). Therefore, this treatment is still associated with a high morbidity and mortality, as well as a high economic burden. Our previous EU FP6 project, ALLOSTEM, resulted in a number of achievements, including a ‘first in man’ clinical trial that used a highly innovative novel cell selection strategy (Streptamer technology) for the generation of non-ATMP (advanced therapy medicinal product) monovirus specific T cell products. Continuing from ALLOSTEM, we now aim to develop two novel Streptamer-based clinical cell selection processes and its corresponding cell products. A multispecific T cell product targeting several viruses and tumors as well as a primary regulatory T cell product targeting GvHD will be developed to market maturity. These two cell products will improve the outcome of allogeneic HSCT. A significant improvement in the outcome and this coupled with a significant reduction of the costs for a large number of patients in Europe will further broaden the application in other forms of cancer of this curative treatment. In order to achieve this goal we assembled a consortium led by the SME Stage cell therapeutics GmbH together with renowned clinical scientists in the field of HSCT (all key players in ALLOSTEM).'

Introduzione (Teaser)

A European study is developing an immunotherapeutic approach based on donor T cells to improve the outcome of haematopoietic cell transplantation. This has direct consequences for the treatment of leukaemia.